{"id":40165,"date":"2026-10-26T15:32:43","date_gmt":"2026-10-26T14:32:43","guid":{"rendered":"https:\/\/ggba.swiss\/alcon-acquires-neurotech-for-usd-550-million\/"},"modified":"2026-10-26T15:36:06","modified_gmt":"2026-10-26T14:36:06","slug":"alcon-a-rachete-neurotech-pour-usd-550-millions","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/","title":{"rendered":"Alcon a rachet\u00e9 Neurotech pour USD 550 millions"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.alcon.com\/\">Alcon<\/a> a rachet\u00e9 <a href=\"https:\/\/www.neurotechpharmaceuticals.com\/\">Neurotech Pharmaceuticals<\/a> et int\u00e8gre ainsi ENCELTO (revakinagene taroretcel-lwey) \u00e0 son portefeuille de la r\u00e9tine. Annonc\u00e9e le 20 octobre 2026, l&rsquo;acquisition a \u00e9t\u00e9 pay\u00e9e USD 550 millions en esp\u00e8ces, et Alcon pourrait devoir verser des paiements conditionnels suppl\u00e9mentaires, dont certains li\u00e9s \u00e0 des jalons commerciaux. Alcon s&rsquo;attend \u00e0 ce que l&rsquo;op\u00e9ration contribue modestement \u00e0 la croissance des ventes nettes et dilue l\u00e9g\u00e8rement le b\u00e9n\u00e9fice dilu\u00e9 par action ajust\u00e9 (core) en 2027, avant de devenir relutive par la suite.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Le premier traitement approuv\u00e9 contre la MacTel de type 2<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">ENCELTO est une th\u00e9rapie g\u00e9nique \u00e0 base de cellules encapsul\u00e9es, implant\u00e9e chirurgicalement dans l&rsquo;\u0153il, destin\u00e9e aux adultes atteints de t\u00e9langiectasie maculaire idiopathique (MacTel) de type 2. Cette maladie r\u00e9tinienne rare et progressive entra\u00eene une perte irr\u00e9versible de la vision centrale et n&rsquo;avait jusqu&rsquo;ici aucun traitement approuv\u00e9. L&rsquo;implant lib\u00e8re en continu le facteur neurotrophique ciliaire humain recombinant, cens\u00e9 contribuer \u00e0 prot\u00e9ger les photor\u00e9cepteurs de la r\u00e9tine. La <a href=\"https:\/\/www.fda.gov\/\">Food and Drug Administration<\/a> (FDA) am\u00e9ricaine l&rsquo;a approuv\u00e9 en mars 2025 apr\u00e8s un examen prioritaire, et il b\u00e9n\u00e9ficie du statut de m\u00e9dicament orphelin. ENCELTO n&rsquo;est actuellement disponible qu&rsquo;aux \u00c9tats-Unis, o\u00f9 environ 25&rsquo;000 patients sont diagnostiqu\u00e9s avec une MacTel de type 2 et 2&rsquo;000 \u00e0 3&rsquo;000 nouveaux cas le sont chaque ann\u00e9e, selon les estimations d&rsquo;Alcon.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Une plateforme de th\u00e9rapie cellulaire pour les maladies oculaires chroniques<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Neurotech est une biotech priv\u00e9e sp\u00e9cialis\u00e9e dans les th\u00e9rapies contre les maladies oculaires chroniques. Sa plateforme Encapsulated Cell Therapy est un syst\u00e8me d&rsquo;administration de m\u00e9dicaments de premi\u00e8re classe : une petite capsule semi-perm\u00e9able contient des cellules d&rsquo;\u00e9pith\u00e9lium pigmentaire r\u00e9tinien allog\u00e9niques g\u00e9n\u00e9tiquement modifi\u00e9es, qui produisent des prot\u00e9ines th\u00e9rapeutiques directement dans l&rsquo;\u0153il.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dans le communiqu\u00e9 de l\u2019entreprise, David Endicott, CEO d&rsquo;Alcon, juge cette plateforme tr\u00e8s compl\u00e9mentaire des capacit\u00e9s actuelles d&rsquo;Alcon. Dan Miller, Distinguished Fellow, Research &amp; Development chez Alcon, affirme que la pr\u00e9sence d&rsquo;Alcon en chirurgie r\u00e9tinienne en fait le partenaire id\u00e9al pour \u00e9largir l&rsquo;acc\u00e8s \u00e0 ENCELTO.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alcon, entreprise de soins oculaires dont le si\u00e8ge mondial est \u00e0 Gen\u00e8ve, a rachet\u00e9 la biotech am\u00e9ricaine Neurotech Pharmaceuticals pour USD 550 millions en esp\u00e8ces, auxquels peuvent s&rsquo;ajouter des paiements conditionnels li\u00e9s \u00e0 des jalons.<\/p>\n","protected":false},"author":6,"featured_media":40161,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1188,1171,1142],"class_list":["post-40165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-healthcare-fr-2","tag-pharma-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alcon a rachet\u00e9 Neurotech pour USD 550 millions | GGBa<\/title>\n<meta name=\"description\" content=\"Alcon a rachet\u00e9 Neurotech pour USD 550 millions et int\u00e8gre ENCELTO, seul traitement approuv\u00e9 par la FDA contre la MacTel de type 2.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alcon a rachet\u00e9 Neurotech pour USD 550 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"Alcon a rachet\u00e9 Neurotech pour USD 550 millions et int\u00e8gre ENCELTO, seul traitement approuv\u00e9 par la FDA contre la MacTel de type 2.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-26T14:32:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-26T14:36:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Alcon-Eye-Treatment-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Alcon a rachet\u00e9 Neurotech pour USD 550 millions\",\"datePublished\":\"2026-10-26T14:32:43+00:00\",\"dateModified\":\"2026-10-26T14:36:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/\"},\"wordCount\":378,\"image\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/10\\\/Alcon-Eye-Treatment-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Healthcare\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/\",\"name\":\"Alcon a rachet\u00e9 Neurotech pour USD 550 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/10\\\/Alcon-Eye-Treatment-1180x811-1.png\",\"datePublished\":\"2026-10-26T14:32:43+00:00\",\"dateModified\":\"2026-10-26T14:36:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Alcon a rachet\u00e9 Neurotech pour USD 550 millions et int\u00e8gre ENCELTO, seul traitement approuv\u00e9 par la FDA contre la MacTel de type 2.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/10\\\/Alcon-Eye-Treatment-1180x811-1.png\",\"contentUrl\":\"https:\\\/\\\/ggba.swiss\\\/app\\\/uploads\\\/2026\\\/10\\\/Alcon-Eye-Treatment-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"Alcon a rachet\u00e9 Neurotech Pharmaceuticals et sa th\u00e9rapie ENCELTO, un implant oculaire contre la MacTel de type 2, une maladie rare de la r\u00e9tine qui d\u00e9truit progressivement la vision centrale.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/alcon-a-rachete-neurotech-pour-usd-550-millions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alcon a rachet\u00e9 Neurotech pour USD 550 millions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/staging.ggba.swiss\\\/en\\\/#\\\/schema\\\/person\\\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\\\/\\\/ggba.swiss\\\/fr\\\/author\\\/pierre-yves-oehrli\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alcon a rachet\u00e9 Neurotech pour USD 550 millions | GGBa","description":"Alcon a rachet\u00e9 Neurotech pour USD 550 millions et int\u00e8gre ENCELTO, seul traitement approuv\u00e9 par la FDA contre la MacTel de type 2.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/","og_locale":"fr_FR","og_type":"article","og_title":"Alcon a rachet\u00e9 Neurotech pour USD 550 millions | GGBa","og_description":"Alcon a rachet\u00e9 Neurotech pour USD 550 millions et int\u00e8gre ENCELTO, seul traitement approuv\u00e9 par la FDA contre la MacTel de type 2.","og_url":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-10-26T14:32:43+00:00","article_modified_time":"2026-10-26T14:36:06+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Alcon-Eye-Treatment-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Alcon a rachet\u00e9 Neurotech pour USD 550 millions","datePublished":"2026-10-26T14:32:43+00:00","dateModified":"2026-10-26T14:36:06+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/"},"wordCount":378,"image":{"@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Alcon-Eye-Treatment-1180x811-1.png","keywords":["Biotech","Healthcare","Pharma","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/","url":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/","name":"Alcon a rachet\u00e9 Neurotech pour USD 550 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Alcon-Eye-Treatment-1180x811-1.png","datePublished":"2026-10-26T14:32:43+00:00","dateModified":"2026-10-26T14:36:06+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Alcon a rachet\u00e9 Neurotech pour USD 550 millions et int\u00e8gre ENCELTO, seul traitement approuv\u00e9 par la FDA contre la MacTel de type 2.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Alcon-Eye-Treatment-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Alcon-Eye-Treatment-1180x811-1.png","width":1180,"height":811,"caption":"Alcon a rachet\u00e9 Neurotech Pharmaceuticals et sa th\u00e9rapie ENCELTO, un implant oculaire contre la MacTel de type 2, une maladie rare de la r\u00e9tine qui d\u00e9truit progressivement la vision centrale."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/alcon-a-rachete-neurotech-pour-usd-550-millions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Alcon a rachet\u00e9 Neurotech pour USD 550 millions"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=40165"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40165\/revisions"}],"predecessor-version":[{"id":40167,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40165\/revisions\/40167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/40161"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=40165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=40165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=40165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}